['diabetes']
['saxagliptin', 'dapagliflozin', 'glimepiride']

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Subjects must be willing and able to give signed and dated written informed consent

          -  Patients with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control

          -  Subjects should have been taking the same daily dose of metformin ≥ 1500 mg

          -  Fasting Plasma Glucose ≤ 270 mg/dL (≤15 mmol/L)

          -  Males and females, aged ≥18 years old at time of screening visit

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test

          -  WOCBP and males must agree to follow instructions for method(s) of contraception for
             the duration of treatment with study drug

        Exclusion Criteria:

          -  Clinical diagnosis of type I diabetes

          -  History of diabetic ketoacidosis

          -  Cardiovascular/vascular diseases within 3 months of the enrollment

          -  Renal disease

          -  Hepatic diseases

          -  History of, or currently, acute or chronic pancreatitis

          -  Hematological and oncological disease/conditions

          -  Patients who have contraindications to therapy being studied

          -  Patients on weight loss program(s)

          -  Replacement or chronic systemic corticosteroid therapy
      